DK0496796T3 - Fremgangsmåde og præparater til inhibering af sygdomme i forbindelse med oxidativ beskadigelse - Google Patents

Fremgangsmåde og præparater til inhibering af sygdomme i forbindelse med oxidativ beskadigelse

Info

Publication number
DK0496796T3
DK0496796T3 DK90915877.6T DK90915877T DK0496796T3 DK 0496796 T3 DK0496796 T3 DK 0496796T3 DK 90915877 T DK90915877 T DK 90915877T DK 0496796 T3 DK0496796 T3 DK 0496796T3
Authority
DK
Denmark
Prior art keywords
spin
trapping
administration
compositions
methods
Prior art date
Application number
DK90915877.6T
Other languages
Danish (da)
English (en)
Inventor
Robert A Floyd
John M Carney
Original Assignee
Oklahoma Med Res Found
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/422,651 external-priority patent/US5025032A/en
Application filed by Oklahoma Med Res Found, Univ Kentucky Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of DK0496796T3 publication Critical patent/DK0496796T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK90915877.6T 1989-10-17 1990-10-17 Fremgangsmåde og præparater til inhibering af sygdomme i forbindelse med oxidativ beskadigelse DK0496796T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/422,651 US5025032A (en) 1989-10-17 1989-10-17 Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
US58917790A 1990-09-27 1990-09-27

Publications (1)

Publication Number Publication Date
DK0496796T3 true DK0496796T3 (da) 1994-10-03

Family

ID=27025701

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90915877.6T DK0496796T3 (da) 1989-10-17 1990-10-17 Fremgangsmåde og præparater til inhibering af sygdomme i forbindelse med oxidativ beskadigelse

Country Status (12)

Country Link
US (4) US5405874A (fr)
EP (1) EP0496796B1 (fr)
JP (5) JP2620413B2 (fr)
KR (1) KR960008230B1 (fr)
AT (1) ATE110565T1 (fr)
AU (4) AU653921B2 (fr)
CA (1) CA2069961C (fr)
DE (1) DE69012138T2 (fr)
DK (1) DK0496796T3 (fr)
ES (1) ES2044829T3 (fr)
HK (1) HK1007281A1 (fr)
WO (1) WO1991005552A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE110565T1 (de) * 1989-10-17 1994-09-15 Oklahoma Med Res Found Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.
US5681845A (en) * 1989-10-17 1997-10-28 Oklahoma Medical Research Foundation DMPO spin trapping compositions and methods of use thereof
US6002001A (en) 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
ATE209908T1 (de) * 1991-06-18 2001-12-15 Oklahoma Med Res Found RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
TW257755B (fr) * 1991-09-12 1995-09-21 Merrell Dow Pharma
US5292746A (en) * 1991-09-12 1994-03-08 Merrell Dow Pharmaceuticals Inc. Cyclic nitrones, pharmaceutical compositions thereof and their use in treating shock
JPH0656669A (ja) * 1992-06-11 1994-03-01 Asahi Breweries Ltd 活性酸素消去作用を持つプテリン誘導体製剤
WO1995011908A1 (fr) * 1993-10-25 1995-05-04 Oklahoma Medical Research Foundation Nouvelles compositions de pieges de spins phosphorees
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
FR2731428B1 (fr) * 1995-03-06 1997-06-06 Centre Nat Rech Scient Derives phosphoryles de nitrones, leur procede de preparation et compositions les contenant
IL123345A (en) * 1995-09-11 2003-07-31 Aventis Pharma Inc Cyclic nitrones and pharmaceutical compositions containing them
EP0888290B1 (fr) 1995-11-17 2006-12-27 Florida International University Agents de piegeage de spin a base d'azulenyl-nitrones, et leurs procedes de fabrication et d'utilisation
WO1997038683A1 (fr) * 1996-04-17 1997-10-23 Oklahoma Medical Research Foundation Traitement de la demence associee a l'infection par le virus du sida (vih-1) au moyen de pieges a radicaux libres a base de nitrone
AU721531B2 (en) * 1996-04-23 2000-07-06 Renovis, Inc. Compositions comprising a nitrone compound for use in treating ocular inflammation
US5900227A (en) * 1996-06-17 1999-05-04 Oklahoma Medical Research Foundation Multicyclic nitrone spin trapping compositions
IL128070A0 (en) * 1996-07-19 1999-11-30 Centaur Pharmaceuticals Inc Furan nitrone compounds
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
US6046232A (en) 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
CN1291980A (zh) * 1998-01-16 2001-04-18 桑道药品有限公司 硫醚呋喃硝酮化合物
JP2002509147A (ja) * 1998-01-16 2002-03-26 センター ファーマシューティカルズ， インコーポレイテッド チオフェンニトロン化合物
US6197826B1 (en) 1998-07-17 2001-03-06 Centaur Pharmaceuticals, Inc. α-(2-hydroxyphenyl) nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
US6339102B1 (en) * 1999-06-09 2002-01-15 The United States Of America As Represented By The Secretary Of The Army Method and composition for treating and preventing retinal damage
AU785365B2 (en) * 2000-03-30 2007-02-08 Oklahoma Medical Research Foundation Butylnitrone containing compositons for inhibition of cancer development
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
AU2002253857A1 (en) 2001-01-08 2002-09-04 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US6762322B1 (en) * 2002-12-20 2004-07-13 Goodyear Tire & Rubber Company Preparation of nitrone derivatives
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
US7125934B1 (en) 2005-06-28 2006-10-24 The Goodyear Tire & Rubber Company Functionalization of living rubbery polymers with nitrones
US8420595B2 (en) * 2006-07-25 2013-04-16 Oklahoma Medical Research Foundation Methods for treating acute acoustic trauma
EP2242360B1 (fr) 2008-02-12 2015-04-08 Tosk, Inc. Adjuvants a la doxorubicine pour reduire la toxicite et leurs procedes d'utilisation
WO2009110585A1 (fr) * 2008-03-07 2009-09-11 国立大学法人熊本大学 Solution échantillon pour la mesure de la résonance paramagnétique des électrons, solide séché de cette solution et procédé de mesure utilisant ces solution et solide
EP2520716B1 (fr) * 2009-04-20 2015-01-21 Volvo Construction Equipment AB Système et procédé de dallage intégré
US9034926B2 (en) 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
US8986739B2 (en) 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
ES2395803B1 (es) * 2011-08-01 2013-12-19 Consejo Superior De Investigaciones Científicas (Csic) - 80% Quinolilnitronas
DE102011088787A1 (de) 2011-12-16 2013-06-20 Evonik Industries Ag Siloxannitrone und deren Anwendung
WO2022169642A1 (fr) * 2021-02-08 2022-08-11 Oklahoma Medical Research Foundation Okn-007 en tant qu'agent thérapeutique pour maladies neurodégénératives

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35112A (en) * 1862-04-29 Improvement in head-rests for car-seats
US35213A (en) * 1862-05-13 Improved hydrant
DE273702C (fr) *
US3396027A (en) * 1964-05-13 1968-08-06 Eastman Kodak Co Method of noodling gelatin dispersions
NL131665C (fr) 1964-05-18
US3296145A (en) * 1965-10-21 1967-01-03 Millmaster Onyx Corp Quaternary ammonium-tertiary amine oxide compositions
US3775122A (en) 1967-07-28 1973-11-27 American Can Co Image production using photosensitive compositions of nitrone which is heat developed
US3834073A (en) * 1971-05-03 1974-09-10 Scm Corp Phenyl nitrone derivatives useful as seed protectants
US3849934A (en) * 1971-05-03 1974-11-26 Scm Corp Alpha-aryl-n-lower alkyl nitrone-containing compositions useful as anti-fungal agents
US3767818A (en) 1971-05-03 1973-10-23 Scm Corp Phenyl nitrone containing compositions useful as anti microbial agents
GB1531278A (en) * 1975-12-15 1978-11-08 Shionogi & Co 9,10-dihydro-9,10-methanoanthracene n-oxide derivatives and the production thereof
GB1588417A (en) * 1977-03-15 1981-04-23 Agfa Gevaert Photoresist materials
US4153722A (en) * 1977-10-06 1979-05-08 William H. Rorer, Inc. Method of treatment
US4214003A (en) * 1977-10-06 1980-07-22 William H. Rorer, Inc. Method of treatment
US4197314A (en) * 1977-10-06 1980-04-08 William H. Rorer, Inc. Method of treating inflammation
US4224340A (en) * 1977-10-06 1980-09-23 William H. Rorer, Inc. Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds
US4870002A (en) * 1981-04-07 1989-09-26 The United States Of America As Represented By The Secretary Of The Air Force Method of prevention of oxidative injury to cells
WO1988005044A1 (fr) * 1986-12-29 1988-07-14 Pharmacia Ab Composes d'oxyde nitreux pour la preparation d'une composition pharmaceutique destinee a la prophylaxie et au traitement de troubles causes par des cellules ischemiques
WO1988005653A1 (fr) * 1987-01-28 1988-08-11 Proctor Peter H Composition a application locale et procede de stimulation de la croissance des cheveux avec des radicaux libres stables
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
ATE110565T1 (de) * 1989-10-17 1994-09-15 Oklahoma Med Res Found Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
JPH10259178A (ja) 1998-09-29
AU710341B2 (en) 1999-09-16
HK1007281A1 (en) 1999-04-09
ES2044829T3 (es) 1995-01-16
AU6613390A (en) 1991-05-16
JPH0925263A (ja) 1997-01-28
CA2069961A1 (fr) 1991-04-18
KR920702220A (ko) 1992-09-03
DE69012138D1 (de) 1994-10-06
US5578617A (en) 1996-11-26
ES2044829T1 (es) 1994-01-16
JP2975587B2 (ja) 1999-11-10
JP2620413B2 (ja) 1997-06-11
AU710342B2 (en) 1999-09-16
EP0496796A1 (fr) 1992-08-05
JP2002179563A (ja) 2002-06-26
AU1131595A (en) 1995-03-23
AU692197B2 (en) 1998-06-04
US5405874A (en) 1995-04-11
CA2069961C (fr) 2000-05-02
JPH05505792A (ja) 1993-08-26
WO1991005552A1 (fr) 1991-05-02
JP2816326B2 (ja) 1998-10-27
AU8310198A (en) 1998-12-24
DE69012138T2 (de) 1995-04-06
US6107315A (en) 2000-08-22
EP0496796B1 (fr) 1994-08-31
KR960008230B1 (ko) 1996-06-21
AU653921B2 (en) 1994-10-20
AU8310298A (en) 1998-10-22
US5681965A (en) 1997-10-28
JPH10259128A (ja) 1998-09-29
ATE110565T1 (de) 1994-09-15

Similar Documents

Publication Publication Date Title
DK0496796T3 (da) Fremgangsmåde og præparater til inhibering af sygdomme i forbindelse med oxidativ beskadigelse
NO884625D0 (no) N-substituerte derivater av 1-desoksynojirimycin og 1-desoksymannojirimycin, fremgangsmaate for deres fremstilling og deres anvendelse i legemiddel.
NO882732L (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
FR2612187B1 (fr) Derives du thiazole actifs sur le systeme cholinergique, leur procede de preparation et compositions pharmaceutiques en contenant
DK0828728T3 (da) Phenyldihydrobenzofuraner
YU47116B (sh) Postupak za dobijanje novih n-supstituisanih benzimidazolskih derivata
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DE59610031D1 (de) Cyclohexyldihydrobenzofurane
SE9401197D0 (sv) Active compounds
IL85228A (en) 1-(4-hydroxy-3,5-di-tert.- butylbenzoyl) homopiperazine, various derivatives thereof, processes for the preparation of these and pharmaceutical compositions containing them
DK122391D0 (da) Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
DK393188D0 (da) Farmaceutisk praeparat til intranasal administrering
NO912414L (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
PT1147105E (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente activo e sua utilizacao no tratamento de doencas vasculares
NO173184C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridin-2,4- og 2,5-dikarboksylsyrederivater
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
DK1115697T3 (da) Umættede hydroximsyrederivater som PARP-inhibitorer
BR9910449A (pt) Composições orais de 8-cloro-6,11-diidro-11-(4-piperidilideno)-5h-benzo[5,6]c icloepta[1,2-b]piridina
DK1231908T3 (da) Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
NO893256L (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
DK0486586T3 (da) Kynurensyrederivater, fremstilling deraf og farmaceutiske præparater, der indeholder dem
ATE91414T1 (de) Hustenstillende zusammensetzungen und ein verfahren zu deren herstellung.
ATE92924T1 (de) Heterocyclische substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.